Denali Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Denali Therapeutics

27/02/2024 13:34

* Denali Therapeutics Inc  DNLI.OQ  reported a quarterly
adjusted
loss of 86 cents​​ per share for the quarter ended in December,
lower than the same quarter last year, when the company reported
EPS of -75 cents.  The mean expectation of sixteen analysts for
the quarter was for a loss of 80 cents per share. Wall Street
expected results to range from -96 cents to -71 cents per share.
    * Reported revenue was zero​; analysts expected $8.36
million. 
    * Denali Therapeutics Inc's reported EPS for the quarter was
a
loss of 86 cents​.
    * The company reported a quarterly loss of $119.47 million.
    * Denali Therapeutics Inc shares had fallen by 21.3% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 0.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 15 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Denali
Therapeutics Inc is $39.00 

This summary was machine generated from LSEG data February 27 at
01:33 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.80          -0.86          Missed
 Sep. 30 2023      -0.80          -0.72          Beat
 Jun. 30 2023      -0.68          1.30           Beat
 Mar. 31 2023      -0.70          -0.80          Missed